All In Biotech

Drug Trial Radar · NCT06086912

A Clinical Study to Compare the Bioavailability of HR17031 in Healthy Subjects at Different Sites

A Single-center, Randomized, Open, Three-period, Three-sequence Crossover Clinical Study to Compare the Bioavailability and Safety of a Single Subcutaneous Injection of HR17031 in Healthy Subjects at Different Sites

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 7, 2023

Primary completion

Dec 12, 2023

Study completion Dec 12, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the bioavailability and safety of HR17031 injection in healthy subjects at different sites.

Conditions

  • Type 2 Diabetes

Interventions

  • HR17031Drug

    Receive a single dose of HR17031 at every period (First period:abdomen. Second period. upper arm. Third period: thigh).

  • HR17031Drug

    Receive a single dose of HR17031 at every period (First period:upper arm. Second period: thigh. Third period: abdomen).

  • HR17031Drug

    Receive a single dose of HR17031 at every period (First period:thigh. Second period: abdomen. Third period: upper arm).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-t)Time frame: Start of treatment up to Day 26
  2. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-∞)Time frame: Start of treatment up to Day 26
  3. After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax)Time frame: Start of treatment up to Day 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.